'OLAP' (OLAparib Regulatory Post-marketing Surveillance)
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
661actual
Sites
18
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-02-01 | actual | When the study began enrolling |
| Primary completion | 2025-07-11 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-11 | actual | The whole study's end, after follow-up |
| First posted | 2020-09-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ovarian Cancer
- Breast Cancer
- Prostate Cancer
- Pancreatic Cancer
Primary outcome
what the primary-completion date above is the date OFSafety (adverse events (AEs), serious AEs (SAEs), adverse drug reactions(ADRs), serious ADRs (SADRs), unexpected AEs/ADRs)
measured For about 1 year since the first dose of the study drug
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed